|
1.
|
|
10 p, 903.6 KB |
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
/
Perl, Alexander E. (University of Pennsylvania) ;
Larson, Richard A (University of Chicago) ;
Podoltsev, Nikolai A. (Yale School of Medicine) ;
Strickland, Stephen (Vanderbilt-Ingram Cancer Center) ;
Wang, Eunice S. (Roswell Park Comprehensive Cancer Center) ;
Atallah, Ehab (Medical College of Wisconsin) ;
Schiller, Gary J. (David Geffen School of Medicine at UCLA) ;
Martinelli, Giovanni (IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" IRST S.r.l) ;
Neubauer, Andreas (Universitätsklinikum Giessen und Marburg GmbH) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Recher, Christian (Centre Hospitalier Universitaire de Toulouse. Institut Universitaire du Cancer de Toulouse Oncopole. Université de Toulouse 3 Paul Sabatier) ;
Yoon, Sung-Soo (Seoul National University Hospital) ;
Maeda, Yoshinobu (Okayama University Hospital) ;
Hosono, Naoko (University of Fukui) ;
Onozawa, Masahiro (Hokkaido University) ;
Kato, Takayrasu (Department of Hematology. University of Tsukuba) ;
Kim, Hee-Je (Catholic Hematology Hospital. College of Medicine. The Catholic University of Korea) ;
Hasabou, Nahla (Astellas Pharma US. Inc.) ;
Nuthethi, Rishita (Astellas Pharma US. Inc.) ;
Tiu, Ramon (Astellas Pharma US. Inc.) ;
Levis, Mark J. (Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins University)
The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib improved the survival of patients with relapsed or refractory (R/R) FLT3-mutated acute myelogenous leukemia (AML) in the phase 3 ADMIRAL trial. [...]
2023 -  10.1016/j.jtct.2022.12.006
Transplantation and Cellular Therapy, Vol. 29 Núm. 4 (april 2023) , p. 265.e1-265.e10
|
|
|
2.
|
|
17 p, 1.2 MB |
Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia : A Matching Adjusted Indirect Comparison
/
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Prawitz, Thibaud (Evidera Inc) ;
Freitag, Andreas (Evidera Inc) ;
Sharma, Anuj (Evidera Inc) ;
Dobi, Balázs (Evidera Inc) ;
Rizzo, Federica (Incyte Biosciences International Sàrl, Morges, Switzerland) ;
Sabatelli, Lorenzo (Incyte Biosciences International Sàrl, Morges, Switzerland) ;
Patos, Petros (Incyte Biosciences International Sàrl, Morges, Switzerland)
Introduction: Efficacy of ponatinib-based treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) has not been compared to imatinib-based treatments in head-to-head clinical trials. [...]
2023 - 10.1007/s12325-023-02497-y
Advances in Therapy, Vol. 40 Núm. 7 (july 2023) , p. 3087-3103
|
|
|
3.
|
|
14 p, 563.4 KB |
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors : The necessity of repeated molecular analysis
/
González-Larriba, José Luis (Hospital Universitario Clínico San Carlos (Madrid)) ;
Lázaro-Quintela, Martín (Complexo Hospitalario Universitario de Vigo) ;
Cobo, Manuel (Hospital Regional Universitario de Málaga) ;
Dómine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ;
Universitat Autònoma de Barcelona
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC) has been the identification of molecular alterations vulnerable to targeted inhibition, such as mutations in the epidermal growth factor receptor (EGFR) gene. [...]
2017 - 10.21037/tlcr.2017.10.03
Translational Lung Cancer Research, Vol. 6 (january 2017) , p. S21-S34
|
|
|
4.
|
|
34 p, 1.3 MB |
Inhibitors of aldehyde dehydrogenases of the 1A subfamily as putative anticancer agents : Kinetic characterization and effect on human cancer cells
/
Jiménez, Rafael (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Pequerul, Raquel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Amor Minguez, Adrián (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Lorenzo Rivera, Julia (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Metwally, Kamel (Zagazig University. Department of Medicinal Chemistry) ;
Avilés, Francesc X (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Parés i Casasampera, Xavier (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Farrés, Jaume (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Aldehyde dehydrogenases (ALDHs) are enzymes catalyzing the NAD(P)+-dependent oxidation of aldehydes to their corresponding carboxylic acids. High ALDH activity has been related to some important features of cancer stem cells. [...]
2019 - 10.1016/j.cbi.2019.04.004
Chemico-Biological Interactions, Vol. 306 (2019) , p. 123-130
|
|
|
5.
|
|
25 p, 1.7 MB |
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
/
O'Brien, Susan (University of California) ;
Hillmen, Peter (St. James University Hospital) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Barr, Paul M (University of Rochester Cancer Center) ;
Fraser, Graeme (McMaster University (Canadà)) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Burger, Jan A. (University of Texas MD Anderson Cancer Center) ;
Dilhuydy, Marie-Sarah (Centre Hospitalier Universitaire Hopitaux de Bordeaux) ;
Hess, Georg (Universitats Medizin Mainz) ;
Moreno Atanasio, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Cramer, Paula (University of Cologne) ;
Liu, Emily (Pharmacyclics LLC. an AbbVie Company) ;
Chang, Stephen (Pharmacyclics LLC. an AbbVie Company) ;
Vermeulen, Jessica (Janssen Research & Development) ;
Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ;
Howes, Angela (Janssen Research & Development) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Patel, Kalpesh (Janssen Pharmaceuticals. Inc) ;
Graef, Thorsten (Pharmacyclics LLC. an AbbVie Company) ;
Valentino, Rudolph (Pharmacyclics LLC. an AbbVie Company) ;
Universitat Autònoma de Barcelona
Ibrutinib, a Bruton's tyrosine kinase inhibitor, has become a standard treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The present pooled safety analysis of 4 randomized controlled studies demonstrated a favorable benefit/risk profile for ibrutinib in patients with CLL/SLL and mantle cell lymphoma. [...]
2018 - 10.1016/j.clml.2018.06.016
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18 Núm. 10 (october 2018) , p. 648-657.e15
|
|
|
6.
|
|
9 p, 1.9 MB |
Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
/
Guglieri-Lopez, Beatriz (Hospital Universitari Doctor Peset (València)) ;
Perez-Pitarch, Alejandro (Hospital Clínico Universitario de València) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Gimenez, Estela (Hospital Clínico Universitario de València) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Rabella, Núria (Institut d'Investigació Biomèdica Sant Pau) ;
Hernandez-Boluda, Juan Carlos (Hospital Clínico Universitario de València) ;
Fox, Maria Laura (Hospital Universitari Vall d'Hebron) ;
Valcárcel, David (Hospital Universitari Vall d'Hebron) ;
Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ;
Ferriols-Lisart, Rafael (Hospital Clínico Universitario de València) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Solano, Carlos (Universitat de València) ;
Navarro, David (Universitat de València) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Piñana, José Luis (Instituto de Salud Carlos III) ;
Universitat Autònoma de Barcelona
The current study evaluates the clinical effect of sirolimus exposure on the occurrence of cytomegalovirus (CMV)DNAemia necessitating preemptive antiviral therapy. A total of 167 consecutive recipients of reduced-intensity conditioning (RIC)allogeneic hematopoietic stem cell transplantation (allo-HSCT)who received sirolimus- and tacrolimus-based graft-versus-host disease (GVHD)prophylaxis and whose CMV serostatus was positive for donors and/or recipients were included in this multicenter retrospective study. [...]
2019 - 10.1016/j.bbmt.2019.01.012
Biology of blood and marrow transplantation, Vol. 25 Núm. 5 (may 2019) , p. 1022-1030
|
|
|
7.
|
|
28 p, 884.5 KB |
Cabozantinib for the treatment of solid tumors : a systematic review
/
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Porta, Camillo (Interdisciplinary Department of Medicine. University of Bari "Aldo Moro) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Apolo, Andrea B. (Center for Cancer Research. National Cancer Institute. National Institutes of Health) ;
Viteri, Santiago (UOMI Cancer Center. Clínica Mi Tres Torres) ;
Rodriguez-Antona, Cristina (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
Martin, Lidia (Ipsen Pharma) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre. Servicio de Oncología Médica)
Background: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. [...]
2022 - 10.1177/17588359221107112
Therapeutic Advances in Medical Oncology, Vol. 14 (2022)
|
|
|
8.
|
|
|
9.
|
|
16 p, 1.4 MB |
Retinal Pigment Epithelium-Secreted VEGF-A Induces Alpha-2-Macroglobulin Expression in Endothelial Cells
/
Lehmann, Guillermo L. (Regeneron Pharmaceuticals. Inc.) ;
Ginsberg, Michael (Angiocrine Bioscience. Inc.) ;
Nolan, Daniel J. (Angiocrine Bioscience. Inc.) ;
Rodríguez, Cristina (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez-González, José (Institut d'Investigació Biomèdica Sant Pau) ;
Zeng, Shemin (Institute for Vision Research. Department of Ophthalmology and Visual Sciences. The University of Iowa) ;
Voigt, Andrew P. (Institute for Vision Research. Department of Ophthalmology and Visual Sciences. The University of Iowa) ;
Mullins, Robert F. (Institute for Vision Research. Department of Ophthalmology and Visual Sciences. The University of Iowa) ;
Rafii, Shahin (Ansary Stem Cell Institute. Department of Medicine. Division of Regenerative Medicine. Weill Cornell Medicine) ;
Rodriguez-Boulan, Enrique (Margaret Dyson Vision Research Institute. Department of Ophthalmology. Weill Cornell Medicine) ;
Benedicto, Ignacio (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
Alpha-2-macroglobulin (A2M) is a protease inhibitor that regulates extracellular matrix (ECM) stability and turnover. Here, we show that A2M is expressed by endothelial cells (ECs) from human eye choroid. [...]
2022 - 10.3390/cells11192975
Cells, Vol. 11 Núm. 19 (october 2022) , p. 2975
|
|
|
10.
|
|
13 p, 2.0 MB |
A Multifunctional Trypsin Protease Inhibitor from Yellow Bell Pepper Seeds : Uncovering Its Dual Antifungal and Hypoglycemic Properties
/
Cotabarren, Juliana (Universidad Nacional de la Plata. Centro de Investigación de Proteínas Vegetales) ;
Ozón, Brenda (Universidad Nacional de la Plata. Centro de Investigación de Proteínas Vegetales) ;
Claver, Santiago (Universidad Nacional de la Plata. Centro de Investigación de Proteínas Vegetales) ;
Geier, Florencia (Universidad Nacional de la Plata. Centro de Investigación de Proteínas Vegetales) ;
Rossotti, Martina (Universidad Nacional de la Plata. Centro de Investigación de Proteínas Vegetales) ;
Garcia-Pardo, Javier (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Obregón, Walter David (Universidad Nacional de la Plata. Centro de Investigación de Proteínas Vegetales) ;
Universitat Autònoma de Barcelona.
Departament de Bioquímica i de Biologia Molecular
Fungal infections are a growing public health concern worldwide and the emergence of antifungal resistance has limited the number of therapeutic options. Therefore, developing novel strategies for identifying and developing new antifungal compounds is an active area of research in the pharmaceutical industry. [...]
2023 - 10.3390/pharmaceutics15030781
Pharmaceutics, Vol. 15, Issue 3 (March 2023) , art. 781
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
